Cargando…
Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitiv...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565958/ https://www.ncbi.nlm.nih.gov/pubmed/32847012 http://dx.doi.org/10.3390/jcm9092726 |
_version_ | 1783596047519449088 |
---|---|
author | Ortiz Zuñiga, Angel Michael Simó, Rafael Rodriguez-Gómez, Octavio Hernández, Cristina Rodrigo, Adrian Jamilis, Laura Campo, Laura Alegret, Montserrat Boada, Merce Ciudin, Andreea |
author_facet | Ortiz Zuñiga, Angel Michael Simó, Rafael Rodriguez-Gómez, Octavio Hernández, Cristina Rodrigo, Adrian Jamilis, Laura Campo, Laura Alegret, Montserrat Boada, Merce Ciudin, Andreea |
author_sort | Ortiz Zuñiga, Angel Michael |
collection | PubMed |
description | Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral. |
format | Online Article Text |
id | pubmed-7565958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75659582020-10-26 Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain Ortiz Zuñiga, Angel Michael Simó, Rafael Rodriguez-Gómez, Octavio Hernández, Cristina Rodrigo, Adrian Jamilis, Laura Campo, Laura Alegret, Montserrat Boada, Merce Ciudin, Andreea J Clin Med Article Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral. MDPI 2020-08-24 /pmc/articles/PMC7565958/ /pubmed/32847012 http://dx.doi.org/10.3390/jcm9092726 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ortiz Zuñiga, Angel Michael Simó, Rafael Rodriguez-Gómez, Octavio Hernández, Cristina Rodrigo, Adrian Jamilis, Laura Campo, Laura Alegret, Montserrat Boada, Merce Ciudin, Andreea Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title_full | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title_fullStr | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title_full_unstemmed | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title_short | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
title_sort | clinical applicability of the specific risk score of dementia in type 2 diabetes in the identification of patients with early cognitive impairment: results of the mopead study in spain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565958/ https://www.ncbi.nlm.nih.gov/pubmed/32847012 http://dx.doi.org/10.3390/jcm9092726 |
work_keys_str_mv | AT ortizzunigaangelmichael clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT simorafael clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT rodriguezgomezoctavio clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT hernandezcristina clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT rodrigoadrian clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT jamilislaura clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT campolaura clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT alegretmontserrat clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT boadamerce clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT ciudinandreea clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain |